EVALUATION OF ORAL ANTICOAGULATION WITH RIVAROXABAN, IN PATIENTS WITH NEW ONSET NON VALVULAR ATRIAL FIBRILLATION

Evaluación de la anticoagulación con Rivaroxaban, en pacientes con fibrilación auricular no valvular de reciente diagnóstico.

Author
Neira, Victor; Departamento de Enfermedades Cardiovasculares Pontificia Universidad Católica de Chile

Corbalán, Ramón; Departamento de Enfermedades Cardiovasculares Pontificia Universidad Católica de Chile

Pereira, Jaime; Departamento de Hematología y Oncología, Pontificia Universidad Católica de Chile

Panes, Olga; Departamento de Hematología y Oncología, Pontificia Universidad Católica de Chile

Garayar, Bernardita; Departamento de Enfermedades Cardiovasculares Pontificia Universidad Católica de Chile

Aizman, Andrés; Departamento de Enfermedades Cardiovasculares Pontificia Universidad Católica de Chile

Llevaneras, Silva; Departamento de Enfermedades Cardiovasculares Pontificia Universidad Católica de Chile

Villarroel, Luis; Departamento de Salud Pública Pontificia Universidad Católica de Chile

Full text
http://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/view/4939
Abstract
Background: Atrial fibrillation (AF) generates a hypercoagulable state with an increased thrombin generation and raised levels of thrombin-antithrombin complexes, which results in a high risk of stroke and thromboembolism. Aim: To evaluate the anticoagulant effect of Rivaroxaban by anti-Xa factor activity and its correlation with thrombin-antithrombin complexes, thrombin generation and prothrombin time in patients newly diagnosed with non-valvular AF. Patients and methods: Prospective study in patients with indication of anticoagulation. Demographic variables, cardiovascular risk factors, CHA2DS2VASc and HAS-BLED scores were recorded. Blood samples were taken at baseline, at 3 and 24 hours after the administration of the drug and at 30 days. Rivaroxaban levels, anti-Xa activity, prothrombin time, thrombin generation and plasma levels of thrombin-antithrombin complexes were determined. Results: We studied 20 patients aged 76.3 ± 8.0 years (60% female) with a CHA2DS2VASc score >2 points. The anti-Xa factor activity correlated with Rivaroxaban plasma levels at 3 hours (r=0.61, p
 
Background: Atrial fibrillation (AF) generates a hypercoagulable state with an increased thrombin generation and raised levels of thrombin-antithrombin complexes, which results in a high risk of stroke and thromboembolism. Aim: To evaluate the anticoagulant effect of Rivaroxaban by anti-Xa factor activity and its correlation with thrombin-antithrombin complexes, thrombin generation and prothrombin time in patients newly diagnosed with non-valvular AF. Patients and methods: Prospective study in patients with indication of anticoagulation. Demographic variables, cardiovascular risk factors, CHA2DS2VASc and HAS-BLED scores were recorded. Blood samples were taken at baseline, at 3 and 24 hours after the administration of the drug and at 30 days. Rivaroxaban levels, anti-Xa activity, prothrombin time, thrombin generation and plasma levels of thrombin-antithrombin complexes were determined. Results: We studied 20 patients aged 76.3 ± 8.0 years (60% female) with a CHA2DS2VASc score >2 points. The anti-Xa factor activity correlated with Rivaroxaban plasma levels at 3 hours (r=0.61, p
 
Metadata
Show full item record